Base de dados : MEDLINE
Pesquisa : N03.880 [Categoria DeCS]
Referências encontradas : 9043 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 905 ir para página                         

  1 / 9043 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29300753
[Au] Autor:Liu W; Shi L; Pong RW; Dong H; Mao Y; Tang M; Chen Y
[Ad] Endereço:Key Lab of Health Technology Assessment (Ministry of Health), Collaborative Innovation Center of Social Risks Governance in Health, School of Public Health, Fudan University, Shanghai, China.
[Ti] Título:Determinants of knowledge translation from health technology assessment to policy-making in China: From the perspective of researchers.
[So] Source:PLoS One;13(1):e0190732, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: For health technology assessment (HTA) to be more policy relevant and for health technology-related decision-making to be truly evidence-based, promoting knowledge translation (KT) is of vital importance. Although some research has focused on KT of HTA, there is a dearth of literature on KT determinants and the situation in developing countries and transitional societies remains largely unknown. OBJECTIVE: To investigate the determinants of HTA KT from research to health policy-making from the perspective of researchers in China. DESIGN: Cross-sectional study. METHODS: A structured questionnaire which focused on KT was distributed to HTA researchers in China. KT activity levels in various fields of HTA research were compared, using one-way ANOVA. Principal component analysis was performed to provide a basis to combine similar variables. To investigate the determinants of KT level, multiple linear regression analysis was performed. RESULTS: Based on a survey of 382 HTA researchers, it was found that HTA KT wasn't widespread in China. Furthermore, results showed that no significant differences existed between the various HTA research fields. Factors, such as attitudes of researchers toward HTA and evidence utilization, academic ranks and linkages between researchers and policy-makers, had significant impact on HTA KT (p-values<0.05). Additionally, collaboration between HTA researchers and policy-makers, policy-relevance of HTA research, practicality of HTA outcomes and making HTA reports easier to understand also contributed to predicting KT level. However, academic nature of HTA research was negatively associated with KT level. CONCLUSION: KT from HTA to policy-making was influenced by many factors. Of particular importance were collaborations between researchers and policy-makers, ensuring policy relevance of HTA and making HTA evidence easier to understand by potential users.
[Mh] Termos MeSH primário: Política de Saúde
Avaliação da Tecnologia Biomédica
Pesquisa Médica Translacional
[Mh] Termos MeSH secundário: Adulto
Idoso
Análise de Variância
China
Estudos Transversais
Análise Fatorial
Feminino
Comunicação em Saúde
Seres Humanos
Colaboração Intersetorial
Modelos Lineares
Masculino
Meia-Idade
Análise de Componente Principal
Pesquisadores/psicologia
Inquéritos e Questionários
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180105
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190732


  2 / 9043 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241901
[Au] Autor:Degeling K; Schivo S; Mehra N; Koffijberg H; Langerak R; de Bono JS; IJzerman MJ
[Ad] Endereço:Health Technology and Services Research Department, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. Electronic address: k.degeling@utwente.nl.
[Ti] Título:Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer.
[So] Source:Value Health;20(10):1411-1419, 2017 12.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: With the advent of personalized medicine, the field of health economic modeling is being challenged and the use of patient-level dynamic modeling techniques might be required. OBJECTIVES: To illustrate the usability of two such techniques, timed automata (TA) and discrete event simulation (DES), for modeling personalized treatment decisions. METHODS: An early health technology assessment on the use of circulating tumor cells, compared with prostate-specific antigen and bone scintigraphy, to inform treatment decisions in metastatic castration-resistant prostate cancer was performed. Both modeling techniques were assessed quantitatively, in terms of intermediate outcomes (e.g., overtreatment) and health economic outcomes (e.g., net monetary benefit). Qualitatively, among others, model structure, agent interactions, data management (i.e., importing and exporting data), and model transparency were assessed. RESULTS: Both models yielded realistic and similar intermediate and health economic outcomes. Overtreatment was reduced by 6.99 and 7.02 weeks by applying circulating tumor cell as a response marker at a net monetary benefit of -€1033 and -€1104 for the TA model and the DES model, respectively. Software-specific differences were observed regarding data management features and the support for statistical distributions, which were considered better for the DES software. Regarding method-specific differences, interactions were modeled more straightforward using TA, benefiting from its compositional model structure. CONCLUSIONS: Both techniques prove suitable for modeling personalized treatment decisions, although DES would be preferred given the current software-specific limitations of TA. When these limitations are resolved, TA would be an interesting modeling alternative if interactions are key or its compositional structure is useful to manage multi-agent complex problems.
[Mh] Termos MeSH primário: Simulação por Computador
Técnicas de Apoio para a Decisão
Modelos Econômicos
Neoplasias de Próstata Resistentes à Castração/terapia
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/metabolismo
Tomada de Decisão Clínica
Seres Humanos
Masculino
Medicina de Precisão/métodos
Antígeno Prostático Específico/metabolismo
Neoplasias de Próstata Resistentes à Castração/patologia
Cintilografia/métodos
Avaliação da Tecnologia Biomédica/métodos
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Biomarkers, Tumor); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  3 / 9043 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241902
[Au] Autor:Olberg B; Fuchs S; Panteli D; Perleth M; Busse R
[Ad] Endereço:Berlin University of Technology, Germany; Federal Joint Committee, Berlin, Germany. Electronic address: britta.olberg@googlemail.com.
[Ti] Título:Scientific Evidence in Health Technology Assessment Reports: An In-Depth Analysis of European Assessments on High-Risk Medical Devices.
[So] Source:Value Health;20(10):1420-1426, 2017 12.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The aim of this study was to examine the scientific evidence on clinical effectiveness and safety used in health technology assessments (HTAs) of high-risk medical devices (MDs) in Europe. METHODS: We applied a systematic approach to identify European institutions involved in HTA and to select reports assessing MDs considered high-risk according to the definition in the new German health care regulation §137h. Reports published between 2010 and 2015 were considered in our subsequent analysis. We used a structured tool based on widely accepted methodologic principles from Drummond's framework to extract key information on the clinical evidence considered in the reports. RESULTS: Out of 1376 identified reports, 93 were eligible for analysis. All reports based their assessment primarily on direct evidence, in most cases (68%) identified through an independent systematic literature search. In more than half the identified studies considered in the reports, clinical evidence for demonstration of effectiveness and safety was of moderate or low quality. Even when systematic reviews and randomized controlled trials were available for assessment, most studies showed an unclear or high risk of bias. CONCLUSIONS: This study confirms that the quality of scientific evidence used in HTA of high-risk MDs is low and therefore the use of evidence needs improvement. The European Commission recently updated the regulation on MDs but mainly focused on the safety of materials and the CE (Conformité Européene [European Conformity]) mark. Our results show that additional changes are necessary, specifically with regard to the marketing authorization process of MDs, with stricter quality requirements based on methodologically robust trials, possibly in combination with other evidence sources.
[Mh] Termos MeSH primário: Segurança de Equipamentos
Equipamentos e Provisões
Avaliação da Tecnologia Biomédica/métodos
[Mh] Termos MeSH secundário: Proteínas de Arabidopsis
Carboidratos Epimerases
Equipamentos e Provisões/efeitos adversos
Europa (Continente)
Seres Humanos
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Arabidopsis Proteins); EC 5.1.3.- (Carbohydrate Epimerases); EC 5.1.3.- (GER1 protein, Arabidopsis)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  4 / 9043 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241883
[Au] Autor:Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
[Ad] Endereço:PAREXEL Access Consulting, PAREXEL International, London, UK. Electronic address: egriffiths27@gmail.com.
[Ti] Título:The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
[So] Source:Value Health;20(10):1245-1251, 2017 12.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Many health technology assessment (HTA) agencies express a preference for randomized controlled trial evidence when appraising health technologies; nevertheless, it is not always feasible or ethical to conduct such comparative trials. OBJECTIVES: To assess the role of noncomparative evidence in HTA decision making. METHODS: The Web sites of the National Institute for Health and Care Excellence (NICE) in the United Kingdom, the Canadian Agency for Drugs and Technologies in Health (CADTH) in Canada, and the Institute for Quality and Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [IQWiG]) in Germany were searched for single HTA reports (published between January 2010 and December 2015). The product, indication, outcome, and clinical evidence presented (comparative/noncomparative) were double-extracted, with any discrepancies reconciled. A noncomparative study was defined as any study not presenting results against another treatment (including placebo or best supportive care), regardless of phase or setting, including dose-ranging studies. RESULTS: A total of 549 appraisals were extracted. Noncomparative evidence was considered in 38% (45 of 118) of NICE submissions, 13% (34 of 262) of CADTH submissions, and 12% (20 of 169) of IQWiG submissions. Evidence submissions based exclusively on noncomparative evidence were presented in only 4% (5 of 118) of NICE appraisals, 6% (16 of 262) of CADTH appraisals, and 4% (6 of 169) of IQWiG appraisals. Most drugs appraised solely on the basis of noncomparative evidence were indicated for cancer or hepatitis C. Positive outcome rates (encompassing recommended/restricted/added-benefit decisions) for submissions presenting only noncomparative evidence were similar to overall recommendation rates for CADTH (69% vs. 68%, respectively), but were numerically lower for NICE (60% vs. 84%, respectively) and IQWiG (17% vs. 38%, respectively) (P > 0.05 for all). CONCLUSIONS: Noncomparative studies can be viewed as acceptable clinical evidence by HTA agencies when these study designs are justifiable and when treatment effect can be convincingly demonstrated, but their use is currently limited.
[Mh] Termos MeSH primário: Tecnologia Biomédica
Tomada de Decisões
Projetos de Pesquisa
Avaliação da Tecnologia Biomédica/métodos
[Mh] Termos MeSH secundário: Canadá
Medicina Baseada em Evidências
Alemanha
Seres Humanos
Ensaios Clínicos Controlados Aleatórios como Assunto
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  5 / 9043 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778240
[Au] Autor:Hatswell AJ; Freemantle N; Baio G
[Ad] Endereço:Department of Statistical Science, University College London, Gower Street, London, WC1E 6BT, UK. ahatswell@bresmed.com.
[Ti] Título:Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy.
[So] Source:Pharmacoeconomics;35(2):163-176, 2017 Feb.
[Is] ISSN:1179-2027
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pharmaceuticals are usually granted a marketing authorisation on the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised comparator group (either active or placebo). OBJECTIVE: To identify and develop a taxonomic account of economic modelling approaches for pharmaceuticals licensed without RCT data. METHODS: We searched PubMed, the websites of UK health technology assessment bodies and the International Society for Pharmacoeconomics and Outcomes Research Scientific Presentations Database for assessments of treatments granted a marketing authorisation by the US Food and Drug Administration or European Medicines Agency from January 1999 to May 2014 without RCT data (74 indications). The outcome of interest was the approach to modelling efficacy data. RESULTS: Fifty-one unique models were identified in 29 peer-reviewed articles, 30 health technology appraisals, and 15 International Society for Pharmacoeconomics and Outcomes Research abstracts concerning 30 indications (44 indications had not been modelled). We noted the high rate of non-submission to health technology assessment agencies (28/98). The majority of models (43/51) were based on 'historical controls'-comparisons to previous meta-analysis or pooling of trials (5), individual trials (16), registries/case series (15), or expert opinion (7). Other approaches used the patient as their own control, performed threshold analysis, assumed time on treatment was added to overall survival, or performed cost-minimisation analysis. CONCLUSIONS: There is considerable variation in the quality and approach of models constructed for drugs granted a marketing authorisation without a RCT. The most common approach is of a naive comparison to historical data (using other trials/registry data as a control group), which has considerable scope for bias.
[Mh] Termos MeSH primário: Aprovação de Drogas
Modelos Econômicos
Preparações Farmacêuticas/administração & dosagem
[Mh] Termos MeSH secundário: Seres Humanos
Preparações Farmacêuticas/economia
Ensaios Clínicos Controlados Aleatórios como Assunto
Avaliação da Tecnologia Biomédica/métodos
Reino Unido
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pharmaceutical Preparations)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1007/s40273-016-0460-6


  6 / 9043 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778526
[Au] Autor:Wojcik A; Oestreicher U; Barrios L; Vral A; Terzoudi G; Ainsbury E; Rothkamm K; Trompier F; Kulka U
[Ad] Endereço:a Department of Molecular Biosciences , Stockholm University, Stockholm, Sweden and Jan Kochanowski University, Institute for Biology , Kielce , Poland .
[Ti] Título:The RENEB operational basis: complement of established biodosimetric assays.
[So] Source:Int J Radiat Biol;93(1):15-19, 2017 01.
[Is] ISSN:1362-3095
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To set up an operational basis of the Realizing the European Network of Biodosimetry (RENEB) network within which the application of seven established biodosimetric tools (the dicentric assay, the FISH assay, the micronucleus assay, the PCC assay, the gamma-H2AX assay, electron paramagnetic resonance and optically stimulated luminescence) will be compared and standardized among the participating laboratories. METHODOLOGY: Two intercomparisons were organized where blood samples and smartphone components were irradiated, coded and sent out to participating laboratories for dosimetric analysis. Moreover, an accident exercise was organized during which each RENEB partner had the chance to practice the procedure of activating the network and to handle large amounts of dosimetric results. RESULTS: All activities were carried out as planned. Overall, the precision of dose estimates improved between intercomparisons 1 and 2, clearly showing the value of running such regular activities. CONCLUSIONS: The RENEB network is fully operational and ready to act in case of a major radiation emergency. Moreover, the high capacity for analyzing radiation-induced damage in cells and personal electronic devices makes the network suitable for large-scale analyses of low doses effects, where high numbers of samples must be scored in order to detect weak effects.
[Mh] Termos MeSH primário: Bioensaio/métodos
Exposição à Radiação/análise
Lesões por Radiação/prevenção & controle
Monitoramento de Radiação/métodos
Proteção Radiológica/métodos
[Mh] Termos MeSH secundário: Emergências
Europa (Continente)
Seres Humanos
Laboratórios/organização & administração
Objetivos Organizacionais
Exposição à Radiação/prevenção & controle
Avaliação da Tecnologia Biomédica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1080/09553002.2016.1235296


  7 / 9043 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28964444
[Au] Autor:Oortwijn W; Determann D; Schiffers K; Tan SS; van der Tuin J
[Ad] Endereço:ECORYS Nederland B.V., Rotterdam, The Netherlands. Electronic address: wija.oortwijn@ecorys.com.
[Ti] Título:Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries.
[So] Source:Value Health;20(8):1121-1130, 2017 Sep.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To assess the level of comprehensiveness of health technology assessment (HTA) practices around the globe and to formulate recommendations for enhancing legitimacy and fairness of related decision-making processes. METHODS: To identify best practices, we developed an evaluation framework consisting of 13 criteria on the basis of the INTEGRATE-HTA model (integrative perspective on assessing health technologies) and the Accountability for Reasonableness framework (deliberative appraisal process). We examined different HTA systems in middle-income countries (Argentina, Brazil, and Thailand) and high-income countries (Australia, Canada, England, France, Germany, Scotland, and South Korea). For this purpose, desk research and structured interviews with relevant key stakeholders (N = 32) in the selected countries were conducted. RESULTS: HTA systems in Canada, England, and Scotland appear relatively well aligned with our framework, followed by Australia, Germany, and France. Argentina and South Korea are at an early stage, whereas Brazil and Thailand are at an intermediate level. Both desk research and interviews revealed that scoping is often not part of the HTA process. In contrast, providing evidence reports for assessment is well established. Indirect and unintended outcomes are increasingly considered, but there is room for improvement. Monitoring and evaluation of the HTA process is not well established across countries. Finally, adopting transparent and robust processes, including stakeholder consultation, takes time. CONCLUSIONS: This study presents a framework for assessing the level of comprehensiveness of the HTA process in a country. On the basis of applying the framework, we formulate recommendations on how the HTA community can move toward a more integrated decision-making process using HTA.
[Mh] Termos MeSH primário: Tomada de Decisões
Modelos Teóricos
Avaliação da Tecnologia Biomédica/métodos
[Mh] Termos MeSH secundário: Países Desenvolvidos
Países em Desenvolvimento
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171002
[St] Status:MEDLINE


  8 / 9043 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28945772
[Au] Autor:Ouimet M; Lalancette P; Racine A
[Ad] Endereço:Department of Political Science, Faculty of the Social Sciences, Université Laval, Québec, Québec, Canada.
[Ti] Título:Health technology assessments conducted in health care facilities: A strategic practice? Findings from a content analysis of HTA reports.
[So] Source:PLoS One;12(9):e0185183, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this paper, we test the hypothesis that health technology assessment units located in hospitals tend to be more optimistic toward technologies that are currently in use in their organization than technologies that are not. The data include 108 health technologies assessed in 87 full-scale health technology assessment reports produced by the four main local health technology assessment units in Quebec (Canada) on behalf of decision makers from the same facility. We found that 58 (53.7 percent) of the 108 technologies were currently in use within the hospital during their assessment. Based on the assessors' interpretation of the scientific evidence regarding the efficacy of the technologies, 67.3 percent of the technologies that were in use in the hospital during the evaluation were effective (56 percent for those that were not currently being used), but the difference is not statistically significant (chi-square 1.38; p = 0.24). Controlling for the efficacy judgment, the type of technologies (i.e. preventive, diagnostic, therapeutic or organizational), the number of technologies assessed in the report and the assessment unit, we found that the technologies that were currently in use in the facility during the evaluation were 62 percent more likely to be recommended favorably by the assessment unit than the technologies that were not currently being used (RR = 1.62; 95 percent CI = 1.06-1.88). This suggests that the local health technology units that were examined in the study tended to be more optimistic toward technologies that were currently in use in their hospital at the time of the evaluation.
[Mh] Termos MeSH primário: Instalações de Saúde
Avaliação da Tecnologia Biomédica
[Mh] Termos MeSH secundário: Interpretação Estatística de Dados
Bases de Dados Factuais
Tomada de Decisões
Hospitais
Seres Humanos
Quebeque
Avaliação da Tecnologia Biomédica/tendências
Avaliação da Tecnologia Biomédica/utilização
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170926
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185183


  9 / 9043 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28785782
[Au] Autor:Saunders D; Raissaki M; Servaes S; Adamsbaum C; Choudhary AK; Moreno JA; van Rijn RR; Offiah AC; Written on behalf of the European Society of Paediatric Radiology Child Abuse Task Force and the Society for Pediatric Radiology Child Abuse Committee
[Ad] Endereço:Great Ormond Street Hospital NHS Trust for Children, Institute of Child Health, WC1N 3JH, London, UK.
[Ti] Título:Throwing the baby out with the bath water - response to the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) report on traumatic shaking.
[So] Source:Pediatr Radiol;47(11):1386-1389, 2017 10.
[Is] ISSN:1432-1998
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Síndrome do Bebê Sacudido
Avaliação da Tecnologia Biomédica
[Mh] Termos MeSH secundário: Seres Humanos
Serviço Social
Suécia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; COMMENT
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE
[do] DOI:10.1007/s00247-017-3932-8


  10 / 9043 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28760835
[Au] Autor:Denburg AE; Ungar WJ; Greenberg M
[Ad] Endereço:Division of Haematology/Oncology (Denburg, Greenberg); Child Health and Evaluative Sciences (Denburg, Ungar), Peter Gilgan Centre for Research and Learning, The Hospital for Sick Children; Institute for Health Policy, Management and Evaluation (Ungar), University of Toronto; Pediatric Oncology Group of Ontario (Greenberg), Toronto, Ont. avram.denburg@sickkids.ca.
[Ti] Título:Public drug policy for children in Canada.
[So] Source:CMAJ;189(30):E990-E994, 2017 07 31.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Aprovação de Drogas
Política de Saúde
Programas Nacionais de Saúde
[Mh] Termos MeSH secundário: Canadá
Criança
Análise Custo-Benefício
Seres Humanos
Avaliação da Tecnologia Biomédica
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1503/cmaj.170380



página 1 de 905 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde